Stocks Health care BMY
NYSE · Health careBristol Myers Squibb Co (BMY)
Bristol Myers Squibb Co brought in $49.2B of revenue over the twelve months to June 30, 2026, up 3.1% from a year earlier. Net income was $9.3B, a net margin of 18.9%. Operating cash flow minus capital spending left $12.8B of free cash flow in fiscal 2025. At June 30, 2026 it held $8.7B in cash against $42.9B of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on July 30, 2026.
What Bristol Myers Squibb Co does
Bristol Myers Squibb discovers, develops, and sells biopharmaceutical medicines. The company focuses on therapeutic areas including oncology, hematology, immunology, and cardiovascular diseases. Its prescription drugs, such as Eliquis and Opdivo, are sold to hospitals, clinics, and pharmacies. Its shares trade on NYSE under the ticker BMY.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $48.2B | $7.1B | $3.46 | $12.8B |
| 2024 | $48.3B | -$8.9B | -$4.41 | $13.9B |
| 2023 | $45B | $8B | $3.86 | $12.7B |
| 2022 | $46.2B | $6.3B | $2.95 | $11.9B |
| 2021 | $46.4B | $7B | $3.12 | $15.2B |
| 2020 | $42.5B | -$9B | -$3.99 | $13.3B |
Latest SEC filings
What Bristol Myers Squibb Co has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 7, 2026Passive stake (5% or more) SCHEDULE 13G
- July 30, 2026Quarterly report 10-Q · period to June 30, 2026
- July 30, 2026
- June 5, 2026
- June 5, 2026
- June 5, 2026
- May 8, 2026
- May 8, 2026
- April 30, 2026Quarterly report 10-Q · period to March 31, 2026
- April 30, 2026
Questions about BMY
What does Bristol Myers Squibb Co do?
Bristol Myers Squibb discovers, develops, and sells biopharmaceutical medicines. The company focuses on therapeutic areas including oncology, hematology, immunology, and cardiovascular diseases. Its prescription drugs, such as Eliquis and Opdivo, are sold to hospitals, clinics, and pharmacies. Its shares trade on NYSE under the ticker BMY.
Is Bristol Myers Squibb Co profitable?
Yes. Over the twelve months to June 30, 2026 it reported net income of $9.3B on revenue of $49.2B, a net margin of 18.9%.
How much revenue does Bristol Myers Squibb Co make?
Over the twelve months to June 30, 2026 Bristol Myers Squibb Co reported revenue of $49.2B. That is 3.1% more than a year earlier.
When did Bristol Myers Squibb Co last report?
Its most recent periodic report is the quarterly report (10-Q) filed on July 30, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from September 10, 2026.
Similar companies
Follow BMY
Get an email when Bristol Myers Squibb Co files with the SEC: results, executive changes, material agreements and annual reports.
Follow BMY: get an email when it filesWhere the numbers come from
Financial figures are the values Bristol Myers Squibb Co tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.